Health Care • Biotechnology: Pharmaceutical Preparations
$0.94 ▼ -0.01
(-0.79%)
MKT CAP: $3.3M • VOL: 73.5K
52W L $1 52W H $9
ROARABLE / RQD
D- • 38/100
PIOTROSKI
5 / 9
SXTP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.0M | $607.6K | $253.6K |
| YoY Revenue Growth % | +65.5% | +139.6% | — |
| Gross Profit | $223.8K | $222.8K | — |
| Gross Margin % | 22.3% | 36.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.8M | -$9.7M | -$5.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$7.4M | -$7.9M | -$3.8M |
| EBITDA (Normalized) | -$7.6M | -$9.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.8M | -$5.6M | -$4.5M |
| Capital Expenditures (CapEx) | $139.9K | $103.8K | — |
| Free Cash Flow (FCF) | -$7.0M | -$5.8M | -$4.5M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.5M | $1.7M | — |
| Total Debt (Short + Long Term) | $144.0K | $147.1K | — |
| Total Stockholders' Equity | $3.5M | $4.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SXTP.